Health Care & Life Sciences » Biotechnology | ImmunoCellular Therapeutics Ltd.

ImmunoCellular Therapeutics Ltd. | Mutual Funds

Mutual Funds that own ImmunoCellular Therapeutics Ltd.

Name
Shares Held
% Shares Out
Change In Shares
% of Assets
As of Date
Vanguard Extended Market Index Fund
284,812
0.68%
0
0%
07/31/2018
10,992
0.03%
0
0.01%
09/05/2018
Fidelity Spartan Extended Market Index Fund
6,339
0.02%
0
0%
07/31/2018
Fidelity Spartan Total Market Index Fund
1,048
0%
0
0%
07/31/2018
iShares Core S&P Total US Stock Market ETF
672
0%
0
0%
09/06/2018
Vanguard Invt. Fds. ICVC - US Equity Index Fund
342
0%
0
0%
06/30/2018

About ImmunoCellular Therapeutics

View Profile
Address
30721 Russell Ranch Road
Westlake Village California 91362
United States
Employees -
Website http://www.imuc.com
Updated 07/08/2019
ImmunoCellular Therapeutics, Ltd. is a clinical-stage company, which engages in the development of immune-based therapies for the treatment of cancers. The company's lead product candidate, ICT-107, is a dendritic cell-based immunotherapy targeting multiple tumor-associated antigens on glioblastoma stem cells. Its pipeline also includes ICT-121, a patient-specific, dendritic cell-based immunotherapy targeting the CD133 antigen on stem cells in recurrent glioblastoma; ICT-140, a patient-specific, dendritic cell-based immunotherapy targeting antigens on ovarian cancer stem cells; and the Stem-to-T-cell research program which engineers the patient's hematopoietic stem cells to generate antigen-specific cancer-killing T cells.